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A B S T R A C T
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited genetic disease
caused by defective desmosomal proteins, and it has typical histopathological features characterized by
predominantly progressive ﬁbro-fatty inﬁltration of the right ventricle. Clinical presentations of ARVD/C
vary from syncope, progressive heart failure (HF), ventricular tachyarrhythmias, and sudden cardiac
death (SCD). The 2010 modiﬁed Task Force criteria were established to facilitate the recognition and
diagnosis of ARVD/C. An implantable cardiac deﬁbrillator (ICD) remains to be the cornerstone in
prevention of SCD in patients fulﬁlling the diagnosis of deﬁnite ARVD/C, especially among ARVD/C
patients with syncope, hemodynamically unstable ventricular tachycardia (VT), ventricular ﬁbrillation,
and aborted SCD. Further risk stratiﬁcation is clinically valuable in the management of patients with
borderline or possible ARVD/C and mutation carriers of family members. However, given the entity of
heterogeneous penetrance and non-uniform phenotypes, the standardization of clinical practice
guidelines for at-risk individuals will be the next frontier to breakthrough.
Antiarrhythmic drugs are prescribed frequently to patients experiencing frequent ventricular
tachyarrhythmias and/or appropriate ICD shocks. Amiodarone is the recommended drug of choice.
Radiofrequency catheter ablation (RFCA) has been demonstrated to effectively eliminate the drug-
refractory VT in patients with ARVD/C. However, the efﬁcacy and clinical prognosis of RFCA via
endocardial approach alone was disappointing prior to the era of epicardial approach. In recent years, it
has been proven that the integration of endocardial and epicardial ablation by targeting the critical
isthmus or eliminating abnormal electrograms within the diseased substrates could yield higher acute
success and lower recurrence of ventricular tachyarrhythmias during long-term follow-up. Heart
transplantation is the ﬁnal option for patients with extensive disease, biventricular HF with
uncontrollable hemodynamic compromise, and refractory ventricular tachyarrhythmias despite
aggressive medical and ablation therapies.
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Arrhythmogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) is an inherited cardiomyopathy, which was ﬁrst
described in 1965 [1]. ARVD/C predominantly affects the right
ventricle (RV) with ﬁbrofatty replacement pathologically. The left
ventricle (LV) involvement, typically the posterior lateral wall,
accounts for an estimated 10% of patients, and presents usually as
one of the late manifestations [2,3]. Mutations of seven dominant
genes in the desmosome result in defective cell-to-cell binding
and contribute to the pathogenesis of ARVD/C.
The presentations of ARVD/C are diverse, ranging from syncope,
heart failure (HF), and sudden cardiac death (SCD). The clinical
courses have been categorized into four phases: concealed phase,
overt electrical disorder, RV failure, and bi-ventricular failure
[3]. Overlapping of each phase may occur. Given the diversity of
disease course, the 2010 modiﬁed Task Force (TF) criteria were
proposed to facilitate the diagnosis [4]. Nevertheless, risk
stratiﬁcation for individuals with ARVD/C and at-risk subjects is
of clinical signiﬁcance. In this review, we summarize current
diagnostic guidelines, risk stratiﬁcation schemes, and the man-
agement of ARVD/C.
Diagnosis of ARVD/C: from past to present
McKenna et al. [5] initially proposed international TF criteria
for the diagnosis of ARVD/C in 1994, and Marcus et al. [4] revised
them (Fig. 1) through the incorporation of new knowledge and
technology to improve the diagnostic sensitivity and yet to
maintain diagnostic speciﬁcity. Quantitative parameters, partic-
ularly imaging studies, were used. Individuals are categorized into
deﬁnite, borderline, or possible diagnosis of ARVD/C after detailed
investigation of structural, histological, electrocardiographic,
arrhythmogenic, family history, and genetic features of the
disease. The modiﬁcation of the TF criteria maintains the major
and minor criteria for each aspect to facilitate clinical diagnosis of
ARVD/C in early stage and ﬁrst-degree relatives with incomplete
expression of the disease [6].
Based on the revised TF criteria, series of evaluations consisting
of non-invasive studies of electrocardiography (ECG), signal
averaged ECG, echocardiogram and/or magnetic resonance imag-
ing (MRI), Holter monitoring, genetic analysis, and invasive studies
of RV angiography, RV endomyocardial biopsy (EMB), are
recommended for individuals at-risk to establish the diagnosis.
Importantly, although 12-lead ECG (Fig. 2) is considered as an
initial screening tool, 12% of patients with ARVD/C may have
normal ECG [7], emphasizing the need for comprehensive clinical
evaluations.Structural abnormalities in ARVD/C can be evaluated by
echocardiogram, MRI noninvasively, or RV angiography inva-
sively. Incorporation of quantitative parameters by echocardiog-
raphy or MRI yields high speciﬁcity (90–98% for major criteria)
[4]. However, the application of revised TF criteria signiﬁcantly
reduced the incidence of structural abnormalities fulﬁlling any
diagnostic criteria than the original criteria [8]. On the other
hand, despite the development of computerized analysis in
quantifying RV abnormalities by angiography [9,10], the pres-
ence of RV akinesia, dyskinesia, or aneurysm remains one of the
major criteria. RV angiography may depict sacculation, segmen-
tal contraction impairment, and variable trabecular patterns in
patients with ARVD/C [11], and therefore, remains the gold
standard for structural assessment in some laboratories.
Distinguishing ARVD/C from other mimicking diagnoses, such
as idiopathic RV outﬂow tract tachycardia (RVOT VT), myocarditis,
sarcoidosis, or endomyocardial ﬁbrosis, is warranted. Assessment
of transmural ﬁbrofatty inﬁltration by means of EMB may provide
valuable histopathological features despite potential risk of free
wall perforation and possibility of false negative results owing to
the nature of segmental involvement. Guiding EMB based on the
low voltage area identiﬁable on electroanatomic mapping (EAM)
may yield higher diagnostic sensitivity [12].
Of note, electrophysiological studies by programmed stimu-
lation (PVS) not only have a pivotal role in evaluating the
vulnerability of ventricular tachyarrhythmias, but provide clues
for the diagnosis of ARVD/C. Denis et al. [13] demonstrated that
either the presence of polymorphic premature ventricular
contractions (PVCs) with 1 couplet or sustained or nonsustained
VT with left bundle branch block (LBBB) after excluding RVOT VT
by high dose isoproterenol (45 mg/min) infusion could help in
making the diagnosis of ARVD/C in the early stage of disease
yielding a sensitivity of 91.4% and a speciﬁcity of 88.9%.
Risk stratiﬁcation and disease progression of ARVD/C
Risk stratiﬁcation in patients with ARVD/C
Several factors have been proposed [2,14–16] for stratifying the
risk of mortality and/or ventricular tachyarrhythmias in ARVD/C.
Corrado et al. [17] established an arrhythmic risk stratiﬁcation
pyramid, which categorized patients with ARVD/C into highest,
intermediate, and lowest risk groups according to the variables
shown in Fig. 3A to facilitate early recognition of individuals who
would be beneﬁt from an implantable cardioverter-deﬁbrillator
(ICD) implantation. Because of a high annual arrhythmic risk up to
8–10%, an ICD implantation is mandatory for those with aborted
SCD, hemodynamically unstable sustained VT, or syncope.
Fig. 1. Current Task Force criteria for the diagnosis of ARVD/C proposed in 2010. Comprehensive evaluations were composed of structural alteration and dysfunction, tissue
characteristics from endomyocardial biopsy, family history, electrocardiographic manifestations of depolarization abnormalities, repolarization abnormalities, and
arrhythmia features. Modiﬁed from Marcus et al. [4]. ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; BSA, body surface area; EDV, end diastolic
volume; EMB, endomyocardial biopsy; LBBB, left bundle branch block; PLAX, parasternal long axis; PSAX, parasternal short axis; RBBB, right bundle branch block; RV, right
ventricular; RVOT, right ventricular outﬂow tract; SAECG, signal-averaged electrocardiogram.
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patientswithARVD/C-associated desmosomalmutations, andsimilarly
classiﬁed subjects into high-, intermediate-, and low-risk groups basedFig. 2. A 35-year-old man presented with syncope and aborted sudden cardiac death. A
complex (epsilon wave) in V1–3 (A2) and diffuse T wave inversion in V1–6. The morphology
morphology and superior axis (indeterminate QRS in lead II, III, and aVF and pos
electrocardiogram (SAECG) (C) also depicted 3+ according to Task Force criteria.on the integrated assessments of the proband’s status, ECG features,
family history, and the density of PVCs from Holter monitoring to
assist risk stratiﬁcation during pedigree evaluation (Fig. 3B). standard electrocardiogram (A1) showed low amplitude signals at the end of QRS
 of clinical ventricular tachycardia (B) was characterized by left bundle branch block
itive in lead aVL) with a tachycardia cycle length of 286 ms. Signal-averaged
Fig. 3. Schemes of arrhythmic risk stratiﬁcation in patients with ARVD/C undergoing ICD therapies (A) and individuals with ARVD/C-associated desmosomal mutations (B).
Subjects were categorized to high, intermediate, and low risk accordingly. Modiﬁed from Corrado et al. [17] and Bhonsale et al. [18]. PVC burden was obtained by a Holter
monitoring. ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; ECG, electrocardiogram; ICD, implantable cardioverter-deﬁbrillator; LV, left ventricle;
PVC, premature ventricular complex; RV, right ventricle; TF, task force; VT, ventricular tachycardia.
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Notwithstanding the progressive nature of ARVD/C, incom-
plete genetic penetrance and variable manifestations suggested
that the clinical phenotype might be inﬂuenced by certain factors.
Endurance training can induce RV enlargement and/or ventricular
tachyarrhythmias in heterozygous plakoglobin-deﬁcient mice
experimentally and desmosomal mutation carriers clinically,
implying the contribution of non-genetic factors on clinical
manifestations in ARVD/C [19,20].
Additionally, Chung et al. [21] found that the accumulation of
ventricular arrhythmia and SCD episodes in patients with ARVD/C
was independently associated with certain meteorological factors
during the summer season, reﬂecting the role of environmental
factors on triggering arrhythmic events. These ﬁndings bring
insight into the education and risk modiﬁcation in patients with
ARVD/C and their relatives.
Management and catheter ablation in ARVD/C
The aim of management of patients with ARVD/C is to prevent
the occurrence of ventricular tachyarrhythmias and SCD, and it has
been traditionally achievable by the incorporation of antiarrhyth-
mic drugs (AADs), ICD, and radiofrequency catheter ablation.
Rarely, heart transplantation is required for patients with severe
diffuse biventricular failure or catastrophic ventricular tachyar-
rhythmias refractory to other treatments. Education on the risk of
SCD and serial evaluations for affected individuals and the relatives
are of clinical importance.
ICD implantation
A previous study investigated the natural history of ARVD/C
with an annual mortality rate of 2.3% [2]. Hodgkinson et al. studied
11 families with ARVD5 (TMEM43 mutation) in a long-term
follow-up, and found a 28% reduction in ﬁve-year mortality in
males with an ICD [22], which was similar to the cumulative
frequency of ICD intervention for fatal ventricular tachyarrhyth-
mias (VT > 240 beats/min). Bhonsale et al. reported an average
incidence of ICD therapies for VF/VFL (ventricular ﬁbrillation/
ventricular ﬂutter) of 4%/year in 84 patients with deﬁnite or
probable ARVD/C [16], and higher incidence of ICD interventions in
probands than in family members (13% vs. 3.4%/year). Regardingthe risk of SCD, individuals with ARVD/C should receive an ICD
implantation as a Class I indication based on current guidelines,
particularly for those with sustained VT/VF who have received
optimal medical therapy [23].
However, it is unknown whether and when the family members
should receive an ICD implantation for primary prevention. In face of
the evidence that electrical abnormalities usually precede detect-
able structural changes in almost one-third of at-risk relatives
during follow-up [24], annual or more frequent electrocardiographic
screening is essential for at-risk family members of patients with
ARVD/C. An ICD implantation may be considered for family
members with SCD, or undiagnosed syncope when ventricular
tachyarrhythmias cannot be excluded as cause of syncope after
optimal medical therapy (Class II indication) [23].
Antiarrhythmic medication
Although ICD implantation is the dominant approach in
prevention of SCD in patients with ARVD/C, empirical AADs
should be considered for patients with a propensity to the
occurrences of VT/VF. Until now, there has been no prospective
study elucidating and comparing the efﬁcacy of individual AADs
in patients with ARVD/C.
Nevertheless, Wichter et al. demonstrated sotalol was effective
in suppression of inducible VT/VF by PVS, whereas Class I AADs
appeared to be ineffective in prevention of either inducible or non-
inducible ventricular tachyarrhythmias in ARVD/C [25]. On the
contrary, in an observation study from North American ARVC
Registry, Marcus et al. found that only amiodarone signiﬁcantly
reduced the risk of clinically relevant ventricular arrhythmias,
while sotalol increased the risk of ventricular tachyarrhythmias
and beta-blockers did not inﬂuence the risk [26]. In this regard,
amiodarone remains as the most effective empirical AAD to
prevent ventricular arrhythmias and ICD shocks in patients with
ARVD/C.
Catheter ablation of ventricular tachyarrhythmias in ARVD/C
Catheter ablation of VT by entrainment mapping has been used
to treat patients with ARVD/C for several years, and the
characteristics of scar-related reentrant VT in ARVD/C are similar
to those in ischemic VT [27]. Despite the advance in techniques in
catheter ablation of VT in patients with ARVD/C, acute success
Fig. 4. An autopsied heart from 33-year-old male with arrhythmogenic right ventricular dysplasia/cardiomyopathy presenting as sudden death. (A) Extensive fatty inﬁltration
of arrhythmogenic triangle (right ventricular outﬂow tract, inﬂow tract, and apex) with right ventricular dilatation. (B) Histopathological examination demonstrated
ﬁbrofatty inﬁltrations extending from epicardium to endocardium, accompanied with localized inﬂammatory changes.
Photos courtesy of the Taiwan National Forensic Department.
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90% [28]. Previously, catheter ablation was reserved only for
patients experiencing drug-refractory ventricular tachyarrhyth-
mias and recurrent ICD shocks due to its limited effectiveness.
Improved understanding of the arrhythmogenic substrates and the
application of epicardial approach in recent years improved the
success rate of eliminating VT in ARVD/C.
Pathogenesis of arrhythmogenic substrates and VT isthmuses
Owing to the ﬁbrofatty replacement of epicardium gradually
toward the endocardium at the RV inﬂow tract, outﬂow tract,
apex, and posterior lateral wall of LV, ventricular arrhythmias,Fig. 5. Epicardial bipolar voltage mapping and the distribution of abnormal electrogram
was extended from right ventricular outﬂow tract to anterior right ventricular free wall,
(yellow tags). (For interpretation of the references to color in this ﬁgure legend, the reincluding PVCs, nonsustained to sustained VT, or VF, originate
from the corresponding locations (Fig. 4) [4]. The process of
ﬁbrofatty inﬁltration is usually accompanied by inﬂammation
initially and the creation of slow conducting channels as the
inhomogeneous ﬁbrosis forms subsequently. Both mechanisms
provide the basis of arrhythmogenic substrates for discontinuous
electrical propagation and explain the cause of ventricular
arrhythmogenesis. Moreover, the different extent of ﬁbrofatty
inﬁltration involving epicardium more than endocardium results
in longer and delayed epicardial activation sequence and
contributes to layered activation of epicardial scar in ARVD/C
rather than transmural activation of RV. This mechanism explainss, consisting of isolated and fractionated late potentials. Widespread epicardial scar
 whereas the abnormal electrograms were distributed within several localized area
ader is referred to the web version of this article.)
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ARVD/C [29].
It was noted that electrical and structural manifestations may
evolve as the disease progresses, as a consequence of the
degenerative nature of ARVD/C. However, in a majority of patients
with ARVD/C undergoing repeat ablation procedures utilizing
detailed EAM, the endocardial substrates showed absence of or
limited macroscopic scar progression [30].
Substrate mapping of endocardium and epicardium
The application of 3-dimensional (3D) navigation systems on
the VT ablation of ARVD/C has been proven to be a more reliable
method. The 3D mapping system helps in realizing the underlying
substrates and results in better prognosis free from VT recurrences.Fig. 6. A1–3 and B1–3 represent voltage mapping of 2 patients with arrhythmogenic ri
endocardial unipolar, and epicardial bipolar voltage mapping, respectively. Endocard
substrates, which was signiﬁcantly smaller than the abnormal area identiﬁed by endocar
was compatible with the abnormal substrates recognized epicardially (<1 mV) (A3 and B
(From C1–3; lower limit: 0.5–0.3–0.1 mV) in patients with ARVD/C provided informatio
voltage threshold, two potential isthmuses were demonstrated at inferior basal right ven
black arrows in C2 and C3). Both of these two isthmuses were responsible for the clinDetailed assessment of the endocardial and epicardial substrates
during sinus rhythm by 3D color-coded voltage mapping,
particularly over the area adjacent to the tricuspid valve region
and the RV outﬂow tract, has provided important insight to
identify the circuits of reentrant VTs within the scar and further
ablation strategies. During sinus rhythm mapping, a cutoff value of
bipolar voltage between 0.5 and 1.5 mV has been traditionally set
up to deﬁne the endocardial substrates [31], whereas the voltage
threshold of 1.0 mV is used for the setting of epicardial bipolar
voltage mapping [32]. Typically, the distribution of epicardial scar
is more extensive than scar identiﬁed endocardially. It is notably
crucial to recognize and acquire the location of fractionated signals
and/or isolated late potentials by EAM, which frequently are
potentially responsible for the VT isthmus (Fig. 5). Finally, pacingght ventricular dysplasia/cardiomyopathy (ARVD/C) regarding endocardial bipolar,
ial voltage mapping (A1 and B1) demonstrated limited and segmental abnormal
dial unipolar voltage mapping (A2 and B2) at a cut-off value of 5.5 mV, and the latter
3). (C) Epicardial voltage mapping (caudal view) by adjusting the voltage threshold
n in identiﬁcation of potential ventricular tachycardia isthmus. After adjusting the
tricle adjacent to the tricuspid annulus and inferior mid right ventricle (indicated by
ically-documented ventricular tachycardias.
Fig. 7. (A) Epicardial voltage mapping after adjusting the voltage thresholds showed 2 potentials isthmuses as shown in Fig. 6C. The potential exit of ventricular tachycardia
(VT) circuit was distal to the isthmus (black arrow; see the following description). Concealed entrainment of clinical VT (B) at inferior basal right ventricle adjacent to inﬂow
tract (star) was achieved with a stimulus to QRS of 127 ms (local electrograms to QRS: 137 ms) and post-pacing interval of 276 ms (tachycardia cycle length: 282 ms). Local
electrograms were also characterized by fractionated electrical activities, preceding QRS by 137 ms, which was compatible with the center of VT isthmus (S-QRS/TCL: 45%).
Best pacemapping site was located distal to the potential isthmus, supporting the activation of VT from basal to the apical direction. (C) Left panel shows that local
electrograms during sinus rhythm ﬁguring as late potentials (yellow dots) at the point (star) with concealed entrainment (the same point as B). The late potentials of the last
two beats was attenuated and eliminated during ablation (right panel) (both electrograms recorded by proximal and distal ablation catheter). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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components of electrograms through different direction of wavelet
propagation [33].
Noteworthy is that the endocardial voltage mapping of RV
not only illustrates the substrates characteristics, but helps in
evaluation of the extent of epicardial abnormalities. First,
evaluation of the abnormal area by using the endocardial
unipolar voltage mapping with a cutoff value of 5.5 mV, and the
abnormal area is correlated to the epicardial scar in ARVD/C
(Fig. 6A and B) [34]. A different cut-off value of 4.4 mV of RV
endocardial unipolar voltage has been proposed by site-by site
correlation [35]. Another method is to analyze the RV endocar-
dial unipolar peak-negative  voltage using a cut-off value of
1.66 mV to predict epicardial dense scar (<0.5 mV) [36].
Mapping of VT and ablation
The VTs in ARVD/C are either monomorphic or multi-
monomorphic, depending on the isthmuses within the abnormal
substrates. The induction of VT in patients with ARVD/C could be
achieved by PVS with isoproterenol. Once the VT is induced, the
morphology should be compared to clinically-documented VT, if
available, and/or the ICD electrograms recorded [37].
For patients with hemodynamically stable sustained VT, both
activation and entrainment mapping can be applied to facilitate the
localization of tachycardia circuits (Fig. 7A and B). The activation
mapping is performed by the acquisition of the earliest electrograms
preceding QRS by at least more than 30 ms, typically characterized
by fractionated or splitting mid-diastolic potentials along the VT
isthmus. Entrainment criteria by measuring the differences between
stimulus to QRS interval and the local electrograms to VT, as well as
the post-pacing interval and the tachycardia cycle length could be
applied to conﬁrm the exit, center, and proximal part of protected
isthmus [31]. Of interest, the endocardial EAM of VT could represent
a focal activation pattern with radial spreading, and usually,
concealed entrainment could be achieved at the earliest activation
site, consistent with exit sites of a reentrant circuit [38]. Even though
the application of pacemapping in scar-related VT is less accurate,pacing surrounding the dense scar bordering can facilitate the
identiﬁcation of the exit site of VT. Linear ablation lesions extending
from the exit site into the identiﬁed isthmus guided by EAM can
effectively terminate the tachycardia. An epicardial approach should
be performed if endocardial ablation fails.
Nevertheless, nonmappable VTs are frequently encountered in
ARVD/C, mostly owing to hemodynamically unstable condition,
multiple reentrant circuit, and nonsustained VT. Substrate
modiﬁcation according to the incorporation of above methods is
usually the strategy of choice to achieve procedural success. The
potential channels and VT isthmuses can be visualized through the
adjustment of voltage limit to assess the widespread scar area
(Fig. 6C) [39], and catheter ablation can be simply performed by
blocking the existence of possible channels between different
voltage areas within the scar in combination with eliminating the
fractionated signals endocardially and epicardially.
Given the likelihood of major complications caused by
percutaneous pericardial puncture, an endocardial approach
remains the initial step, although epicardial circuits are frequently
present in ARVD/C. Additionally, the presence of epicardial fat can
result in voltage mapping resembling dense scar tissues, and also
impede the penetration of energy to the protected isthmus
[40]. Furthermore, a recent study showed that endocardial ablation
was able to eliminate the epicardial local abnormal ventricular
activities (LAVA) in 73% of patients with ARVD/C, implying the
endocardial RFCA is feasible to be used as initial strategy so as to
reduce the need and risk of epicardial ablation [41].
To date, the most common energy source applied for VT
ablation is radiofrequency. A 4-mm irrigated-tip catheter is widely
accepted to be more effective to create deeper lesions for
intramural or epicardial circuits. In our laboratory, power delivery
is usually initiated at 30 W for endocardial site and 20 W for
epicardium. The energy is titrated up to a maximum of 40 W for
endocardium and 35 W for epicardium while targeting an
impedance drop of 10 V by maintaining for a minimum of 120 s
to site of termination in stable VT or the disappearance of abnormal
potentials at each point for substrate modiﬁcation (Fig. 7C).
Table 1
Clinical outcome of VT ablation in ARVD/C.
Author Number of
patients
Mapping
strategies
Sites of
targets
Acute results Follow-up
duration
Short-term free
from VA (1 year)
Long-term free
from VA
Dalal
et al. [42]
24 Conventional
or 3D mapping
Endocardial 46% for all inducible
VT; 31% for clinical VT;
23% procedural failure
32  36
months
50% (5 months) 25% (14 months)
Verma
et al. [43]
22 3D mapping Endocardial 82% 37 months
(median)
77% (1 year) 53% (5 years)
Garcia
et al. [44]
13 3D mapping Endocardial +
epicardial
92% (for all targeted VT) 18  13
months
– 77%
Philips
et al. [45]
87 Conventional
or 3D mapping
Endocardial +
epicardial
Complete success 47%;
partial success 38%;
procedural failure 15%
88.3  66.1
months
1 year: 47%
(endocardial: 45%;
epicardial 64%)
5 years: 21%; 10 years:
15% (5 year-endocardial
19%; 5 year-epicardial 45%)
Bai
et al. [46]
49a Conventional
or 3D mapping
Endocardial +
epicardial
Polymorphic VT/VF:
1 from group 1 and
2 from group 2
At least
3 yearsb
300 days follow-up
(group 1: 88.5%;
group 2: 100%)
3 year follow-up (group 1:
52.2%; group 2 84.6%)
ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
a Group 1: endocardial alone = 23; group 2: endo + epicardial = 26.
b Group 1: 1224  310 days; group 2: 1175  112 days.
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Reviewing the literature [42–46] (Table 1), the outcome of
ablation in ARVD/C has been studied with heterogeneous results,
which were mostly explained by limited case numbers, the
different ablation strategies, distinct disease stages, and variable
follow-up duration. Generally, in the era of endocardial ablation,
the long-term efﬁcacy in prevention of VT recurrence could be
achieved in only 25–53% of cases [40,43]. Advances in the
understanding of underlying pathophysiology have brought
forward ablation to the epicardial era [44]. Recent studies
demonstrated a signiﬁcant beneﬁt of freedom from ventricular
tachyarrhythmias or ICD therapy by 45–84.6% with the combina-
tion of endocardial and epicardial ablation [45,46]. Even though
there has been great improvement in catheter ablation techniques
and outcomes, a clinical hurdle remains in the realm of treating
patients after failed epicardial ablation and patients with rapid
disease progression. These challenges remain to be addressed by
future breakthroughs.
Heart transplantation
Heart transplantation in ARVD/C is reserved seldom for patients
with extensive HF or drug-refractory ventricular tachyarrhythmias
unresponsive to other invasive interventions. Tedford et al.
reported 18 patients with ARVD/C from over 1000 subjects in a
registry undergoing cardiac transplantation, including 13 for HF
and 5 for refractory VT [47]. Whether the advances in the
understanding of pathophysiological characteristics and techni-
ques in catheter ablation in the recent few years would attenuate
the entity of disease progression and incidence of cardiac
transplantation needs complementary studies.
Furthermore, load-reducing therapy with diuretics and
nitrates could prevent the development of ARVD/C in heterozy-
gous plakoglobin-deﬁcient mice receiving endurance training
[19,48]. The clinical implication of load-reducing therapy on
preventing the development and progression in different stages
of ARVD/C requires prospective investigation.
Conclusions
In summary, ARVD/C is an inherited progressive disease. Early
investigation and risk stratiﬁcation is essential for successful
management. An accurate diagnosis is based on detailed evalua-
tion of cardiac imaging, ECG, histopathology, family history,
electrophysiological study, and genetic screening. Therapeutic
options involving ICD, antiarrhythmic drugs, catheter ablation, andrarely heart transplantation are the current mainstay of treat-
ments in prevention of SCD and ventricular tachyarrhythmias.
With understanding of the underlying substrate properties, and
improvement of navigation system, mapping, and epicardial
ablation techniques, the prognosis of VT ablation in ARVD/C has
improved tremendously.
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